ИСТИНА |
Войти в систему Регистрация |
|
ИПМех РАН |
||
Sodiumglucose cotransporter 2 inhibitor empagliflozin (Empa) reduces death from cardiovascular causes, death from any cause, hospitalisation rate for heart failure in patients with diabetes mellitus type 2. In our previous publications comparative efficacy monotherapy of Empa for chronic heart failure (CHF) relative baseline drugs was shown (second stage).